H. Abali Et Al. , "A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).," Gastrointestinal Cancers Symposium , vol.34, San-Francisco, Costa Rica, 2016
Abali, H. Et Al. 2016. A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).. Gastrointestinal Cancers Symposium , (San-Francisco, Costa Rica).
Abali, H., Yalcin, S., Onal, H. C., Dane, F., Oksuzoglu, B., Ozdemir, N., ... Mertsoylu, H.(2016). A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study). . Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica
Abali, HÜSEYİN Et Al. "A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).," Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 2016
Abali, HÜSEYİN Et Al. "A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).." Gastrointestinal Cancers Symposium , San-Francisco, Costa Rica, 2016
Abali, H. Et Al. (2016) . "A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).." Gastrointestinal Cancers Symposium , San-Francisco, Costa Rica.
@conferencepaper{conferencepaper, author={HÜSEYİN ABALI Et Al. }, title={A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).}, congress name={Gastrointestinal Cancers Symposium}, city={San-Francisco}, country={Costa Rica}, year={2016}}